Mp58-02 Organ-Confined Pt2 Isup4/5 vs. Non-Organ Confined ≥pt3 Isup2/3 Prostate Cancer: Differences in Biochemical Recurrence-Free Survival and Metastasis-Free Survival After Radical Prostatectomy

You have accessJournal of UrologyProstate Cancer: Localized: Surgical Therapy III (MP58)1 May 2024MP58-02 ORGAN-CONFINED PT2 ISUP4/5 VS. NON-ORGAN CONFINED ≥PT3 ISUP2/3 PROSTATE CANCER: DIFFERENCES IN BIOCHEMICAL RECURRENCE-FREE SURVIVAL AND METASTASIS-FREE SURVIVAL AFTER RADICAL PROSTATECTOMY Mike Wenzel, Carolin Siech, Benedikt Hoeh, Eike Rohlsen, Cristina Cano Garcia, Clara Humke, Jens Köllermann, Pierre Karakiewicz, Luis Kluth, Felix Chun, and Philipp Mandel Mike WenzelMike Wenzel , Carolin SiechCarolin Siech , Benedikt HoehBenedikt Hoeh , Eike RohlsenEike Rohlsen , Cristina Cano GarciaCristina Cano Garcia , Clara HumkeClara Humke , Jens KöllermannJens Köllermann , Pierre KarakiewiczPierre Karakiewicz , Luis KluthLuis Kluth , Felix ChunFelix Chun , and Philipp MandelPhilipp Mandel View All Author Informationhttps://doi.org/10.1097/01.JU.0001008852.83523.41.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To test for differences in organ vs. non-organ confined pathologic tumor stage and low vs. high International Society of Urological Pathologists (ISUP) grading at radical prostatectomy (RP) and biochemical recurrence (BCR)-free survival (BCRFS), as well as metastasis free survival (MFS) after RP. METHODS: Relying on a tertiary-care database, prostate cancer patients undergoing RP between 01/2014 and 12/2021 were stratified according to their combination of pathologic tumor stage (pT) and ISUP grade group on RP specimens (pT2 ISUP4/5 vs. pT3/4 ISUP2 vs. pT3/4 ISUP3). Kaplan-Meier survival analyses and multivariable Cox regression models (CRM) were separately fitted for BCRFS and MFS after RP. RESULTS: Of 215 eligible RP prostate cancer patients, 29 (13%) exhibited pT2 ISUP4/5 vs. 122 (57%) pT3/4 ISUP2 vs. 64 (30%) pT3/4 ISUP3 pathology after RP. In survival analyses, three-year BCRFS rates were 95% in pT2 ISUP4/5 vs. 88% in pT3/4 ISUP2 vs. 65% in pT3/4 ISUP3 patients (p<0.01). In multivariable CRM predicting BCR, pT3/4 ISUP3 pathology was associated with higher BCR rate relative to pT2 ISUP4/5 pathology (hazard ratio: 3.1, CI: 1.02-9.56; p=0.045), but not pT3/4 ISUP2 pathology (p=0.8). Addressing MFS, three-year rates were 95%, in pT2 ISUP4/5 vs. 98% in pT3/4 ISUP2 vs. in 87% pT3/4 ISUP3 patients (p=0.1). CONCLUSIONS: Compared to prostate cancer patients with pT2 ISUP4/5 pathology, the combination of pT3/4 ISUP3 pathology is associated with a higher BCR rate after RP. In consequence, patients with pT3/4 ISUP3 pathology should be considered for a closer postoperative follow-up. Download PPTDownload PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e947 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Mike Wenzel More articles by this author Carolin Siech More articles by this author Benedikt Hoeh More articles by this author Eike Rohlsen More articles by this author Cristina Cano Garcia More articles by this author Clara Humke More articles by this author Jens Köllermann More articles by this author Pierre Karakiewicz More articles by this author Luis Kluth More articles by this author Felix Chun More articles by this author Philipp Mandel More articles by this author Expand All Advertisement PDF downloadLoading ...